We are monitoring the impact of COVID-19 on Biopharmaceuticals Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 581
Share on
Share on

Global Biopharmaceuticals Market Size, Share, Trends, Growth, COVID-19 Impact Analysis Report - Segmented By Product Type, Therapeutic Type and Region – Industry Forecast (2021 to 2026)

Pulished: February, 2020
ID: 581
Pages: 175

Global Biopharmaceuticals Market Size (2021 to 2026)

As per our research report, the global biopharmaceutical market size is estimated to be growing at a CAGR of 9.2% during the forecast period. The market size was worth USD 192.46 billion in 2020 and forecasted to worth USD 326.3 billion by 2026. Companies such as Amgen Inc., Abbvie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, and Novo Nordisk are forecasted to account for a significant biopharmaceuticals market share in the global market during the forecast period.

Disease treatment techniques have been revolutionized using Biopharmaceuticals or biologics because of their efficiency against autoimmune diseases & cancer and better mode of action. The healthcare industry is expected to make a shift from traditional small molecule drugs to Biopharmaceuticals.

Biopharmaceuticals are drugs obtained from genetically modified sources through biotechnology methods such as hybridoma techniques, recombinant DNA techniques, and purification processes. These drugs are used to treat various diseases like cancer, metabolic, neurological, cardiovascular, and other rare diseases. Biopharmaceuticals have enhanced the quality of life of patients and improved the quality of healthcare.

Biopharmaceuticals are large and complex molecular drugs mainly obtained from nucleic acids and proteins of living organisms such as microorganisms and animal cells, also known as transgenic organisms. These drugs are obtained using biotechnological techniques, and these drugs have higher therapeutic values. The biopharmaceutical market deals with biologics and biotech drugs. These are usually administered by intravenous, subcutaneous, or intramuscular injections and are more efficient than conventional small molecule drugs. Some biopharmaceuticals include monoclonal antibodies, erythropoietin, growth hormones, recombinant proteins, recombinant human insulin, purified proteins, interferon, and vaccines. Recombinant human insulin was amongst the first substances to be approved for therapeutic purposes. Currently, there are nearly 300 biopharmaceutical products that have been approved and are available in the market.

MARKET DRIVERS:

The rising geriatric population prone to neurodegenerative and autoimmune disorders provides a strong business base to the global biopharmaceuticals market.

There is a massive demand for Biopharmaceuticals due to the increasing incidence of chronic diseases whose treatment is made possible using these drugs. The major drivers contributing to the growth of the biopharmaceuticals market are the increased geriatric population globally and the rise in the prevalence of chronic conditions. An increase in the occurrence of vulnerable diseases such as cancer and diabetes, growth in the obesity and sedentary lifestyle among the population, and growing acceptance for biopharmaceuticals due to their ability to treat previously untreatable diseases are further significantly driving the market growth. According to WHO, cancer is the leading cause of death globally, and diabetic patients are also increasing daily due to lifestyle changes. A sedentary lifestyle leads to several chronic diseases, thus boosting the market growth. Biopharmaceuticals hold the potential to cure the disease entirely and not just the symptoms, hence increasing its acceptance.

MARKET RESTRAINTS:

Side effects associated with the over-consumption of drugs and the high manufacturing cost are few restraints for the global biopharmaceuticals market.

There are market restraints for the biopharmaceuticals market, which is holding back the growth of this market. High costs are associated with the drug development process. The threat of failure of drugs, challenging developments affects market growth. With a price of 100 million USD, generally, it takes 5 to 9 years to develop a biopharmaceutical product. This regulatory framework for establishment takes over a lot of work and patience. World Health Organization (WHO) also has set strict approval standards for biopharmaceuticals, which is further estimated to restrict the growth scope of the market to some extent.

COVID-19 impact on the global biopharmaceuticals market:

COVID-19 has a significant impact on every medical industry, likewise biopharmaceuticals. The disruptive effects of COVID-19 have placed enormous strain on the global supply of pharmaceutical products, biologics, and biological preparations. Manufacturing devices and preparative materials such as API, etc., faced a supply shortage due to the crisis in COVID-19. Most of the materials and devices necessary are expected to get delivered on time but affected due to the COVID-19 pandemic. As most manufacturers are from China, this affected the market growth in all other countries and slowed down production.

Due to the pandemic crisis's still going, it showed an impact on research and developmental activities. The funds have been holder by many organizations. Researchers, scientists, doctor's and other staff are the most affected set of people by COVID-19.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Product Type, Therapeutic Type, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East, and Africa

 

This research report on the global biopharmaceuticals market segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2025.

Biopharmaceuticals Market – By Product Type:

The Monoclonal antibodies segment holds the highest number of shares in the product sector based on the product type. Monoclonal antibodies are the technology that is the most emerging technologies. Monoclonal antibodies are identical to immune cells and represent a copy of the unique parent cell. Monoclonal antibodies alone contribute 40% of the global biopharmaceutical market.

Biopharmaceuticals Market – By Therapeutic Type:

  • Neurology               
  • Infectious diseases              
  • Diabetes  
  • Oncology 
  • Cardiovascular       
  • Other Therapeutic Areas  

In terms of therapeutic application, oncology is the largest segment in the Biopharmaceuticals market.

Biopharmaceuticals Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Geographically, North America is the largest market for Biopharmaceuticals across the globe. Technological advancement in the region is propelling the dominance of the area. In North America, the United States biopharmaceuticals market holds the largest market share of 46%, followed by Canada.

Asia-Pacific is forecasted to develop as the fastest-growing region for the global Biopharmaceuticals market in the forecast period. Increasing awareness regarding biological drugs is driving the market in the area. Asia-Pacific is expected to grow at a steady pace of CAGR 8.34% throughout the forecast. Because of an increase in R&D investment, a rise in the adoption and availability of biopharmaceuticals for disease treatment, and a surge in disease diagnosis awareness. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), U.S. firms conduct over half the world's research and development(R&D) in pharmaceuticals and hold the intellectual property rights on most new medicines. The LAMEA region is also expected to boost market growth. Europe is the second-largest Biopharmaceuticals market in the world. The European biopharmaceutical market alone is projected to increase USD 44.26 billion in 2020 and is estimated to be growing at a CAGR of 8.89% to reach USD 67.76 billion by 2025.

KEY MARKET PLAYERS:

List of crucial competitors dominating the global Biopharmaceuticals market profiled in this report are Merck & Co., Inc., F. Hoffmann-La Roche AG, Eli Lilly and Company, Inc., Sanofi, Amgen Inc., AbbVie Inc., Biogen Idec, Bayer AG, Johnson & Johnson Services, Pfizer, Inc. and Novartis AG.

NOTABLE HAPPENINGS IN THIS MARKET IN THE RECENT PAST:

  • On January 05, 2021, Pfizer Inc. and Biopharmaceutical New Technologies (BioNTech) developed a COVID 19 vaccine. These two biopharmaceutical companies become the first to receive emergency validation from the WHO. 
  • On September 03, 2020, Sanofi and GlaxoSmithKline Plc, have collaborated to develop a COVID 19 vaccine. The vaccine developed is ready to begin human trials. These two vaccine makers have started their trials across 11 sites in the United States.
  • On December 24, 2020, Amgen Inc. acquired a drug known as AMG634 and bought Otezla from Celgene in 2019 for $13.4 billion. Amgen Inc. has received a license to treat tuberculosis and leprosy, one of the investigational pipeline drugs to Medicines Development for Global Health.
  • On July 30, 2020, SomaLogic enlarged its collaboration to discover a new drug with giant biopharmaceutical Amgen Inc. SomaLogic uses more than 40,000 blood samples to quantity different biomarkers clinical trial patients.
  • On August 10, 2020, Biogen’s BLA Aducanumab accepted the FDA's priority review for Alzheimer’s diseases, and it is co-developing with Eisai. This will be the first therapy for the clinical decline in Alzheimer’s diseases if the drug is approved.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments                               

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 By Product Type                       

                                5.1.1 Monoclonal Antibodies (mAb)       

                                5.1.2 Erythropoietin       

                                5.1.3 Biotech Vaccines  

                                5.1.4 Recombinant Human (RH) Insulin 

                                5.1.5 Granulocyte colony-stimulating factor (G-CSF)       

                                5.1.6 Interferon               

                                5.1.7 Human growth hormones (HGH)  

                5.2 By Therapeutic Type                               

                                5.2.1 Neurology               

                                5.2.2 Infectious diseases              

                                5.2.3 Diabetes  

                                5.2.4 Oncology 

                                5.2.5 Cardiovascular       

                                5.2.6 Other Therapeutic Areas  

6. Geographical Analysis                                              

                6.1 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.2 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.3 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 South Korea           

                                6.3.6 Australia   

                6.4 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Mexico     

                                6.4.4 Argentina

                                6.4.5 Rest of Latin America          

                6.5 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Merck & Co.                               

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Strategic Evaluation and Operations            

                                8.1.4 Financial analysis  

                                8.1.5 Legal issues             

                                8.1.6 Recent Developments       

                                8.1.7 SWOT analysis       

                                8.1.8 Analyst View          

                8.2 F. Hoffmann-La Roche AG                    

                8.3 Eli Lilly and Company                              

                8.4 Sanofi                           

                8.5 Amgen Inc.                 

                8.6 AbbVie Inc.                 

                8.7 Biogen Idec                

                8.8 Bayer AG                     

                8.9 Johnson & Johnson Services                               

                8.10 Pfizer                          

                8.11 Novartis AG                             

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Expert Opinions                                        

                10.1 Market Outlook                     

                10.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Biopharmaceuticals Market, By Region, From 2021 to 2026 (USD Billion)
  2. Global Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  3. Global Monoclonal Antibodies (mAb) Market, By Region, From 2021 to 2026 (USD Billion)
  4. Global Erythropoietin Market, By Region, From 2021 to 2026 (USD Billion)
  5. Global Biotech Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  6. Global Recombinant Human (RH) Insulin Market, By Region, From 2021 to 2026 (USD Billion)
  7. Global Granulocyte colony-stimulating factor (G-CSF) Market, By Region, From 2021 to 2026 (USD Billion)
  8. Global Interferon Market, By Region, From 2021 to 2026 (USD Billion)
  9. Global Human growth hormones (HGH) Market, By Region, From 2021 to 2026 (USD Billion)
  10. Global Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  11. Global Neurology Market, By Region, From 2021 to 2026 (USD Billion)
  12. Global Infectious diseases Market, By Region, From 2021 to 2026 (USD Billion)
  13. Global Diabetes Market, By Region, From 2021 to 2026 (USD Billion)
  14. Global Oncology Market, By Region, From 2021 to 2026 (USD Billion)
  15. Global Cardiovascular Market, By Region, From 2021 to 2026 (USD Billion)
  16. Global Other Therapeutic Areas Market, By Region, From 2021 to 2026 (USD Billion)
  17. North America Biopharmaceuticals Market, By Region, From 2021 to 2026 (USD Billion)
  18. North America Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  19. North America Monoclonal Antibodies (mAb) Market, By Region, From 2021 to 2026 (USD Billion)
  20. North America Erythropoietin Market, By Region, From 2021 to 2026 (USD Billion)
  21. North America Biotech Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  22. North America Recombinant Human (RH) Insulin Market, By Region, From 2021 to 2026 (USD Billion)
  23. North America Granulocyte colony-stimulating factor (G-CSF) Market, By Region, From 2021 to 2026 (USD Billion)
  24. North America Interferon Market, By Region, From 2021 to 2026 (USD Billion)
  25. North America Human growth hormones (HGH) Market, By Region, From 2021 to 2026 (USD Billion)
  26. North America Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  27. North America Neurology Market, By Region, From 2021 to 2026 (USD Billion)
  28. North America Infectious diseases Market, By Region, From 2021 to 2026 (USD Billion)
  29. North America Diabetes Market, By Region, From 2021 to 2026 (USD Billion)
  30. North America Oncology Market, By Region, From 2021 to 2026 (USD Billion)
  31. North America Cardiovascular Market, By Region, From 2021 to 2026 (USD Billion)
  32. North America Other Therapeutic Areas Market, By Region, From 2021 to 2026 (USD Billion)
  33. United States Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  34. United States Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  35. Canada Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  36. Canada Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  37. Europe Biopharmaceuticals Market, By Region, From 2021 to 2026 (USD Billion)
  38. Europe Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  39. Europe Monoclonal Antibodies (mAb) Market, By Region, From 2021 to 2026 (USD Billion)
  40. Europe Erythropoietin Market, By Region, From 2021 to 2026 (USD Billion)
  41. Europe Biotech Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  42. Europe Recombinant Human (RH) Insulin Market, By Region, From 2021 to 2026 (USD Billion)
  43. Europe Granulocyte colony-stimulating factor (G-CSF) Market, By Region, From 2021 to 2026 (USD Billion)
  44. Europe Interferon Market, By Region, From 2021 to 2026 (USD Billion)
  45. Europe Human growth hormones (HGH) Market, By Region, From 2021 to 2026 (USD Billion)
  46. Europe Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  47. Europe Neurology Market, By Region, From 2021 to 2026 (USD Billion)
  48. Europe Infectious diseases Market, By Region, From 2021 to 2026 (USD Billion)
  49. Europe Diabetes Market, By Region, From 2021 to 2026 (USD Billion)
  50. Europe Oncology Market, By Region, From 2021 to 2026 (USD Billion)
  51. Europe Cardiovascular Market, By Region, From 2021 to 2026 (USD Billion)
  52. Europe Other Therapeutic Areas Market, By Region, From 2021 to 2026 (USD Billion)
  53. U.K Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  54. U.K Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  55. Spain Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  56. Spain Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  57. Germany Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  58. Germany Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  59. Italy Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  60. Italy Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  61. France Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  62. France Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  63. Asia-Pacific Biopharmaceuticals Market, By Region, From 2021 to 2026 (USD Billion)
  64. Asia-Pacific Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  65. Asia-Pacific Monoclonal Antibodies (mAb) Market, By Region, From 2021 to 2026 (USD Billion)
  66. Asia-Pacific Erythropoietin Market, By Region, From 2021 to 2026 (USD Billion)
  67. Asia-Pacific Biotech Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  68. Asia-Pacific Recombinant Human (RH) Insulin Market, By Region, From 2021 to 2026 (USD Billion)
  69. Asia-Pacific Granulocyte colony-stimulating factor (G-CSF) Market, By Region, From 2021 to 2026 (USD Billion)
  70. Asia-Pacific Interferon Market, By Region, From 2021 to 2026 (USD Billion)
  71. Asia-Pacific Human growth hormones (HGH) Market, By Region, From 2021 to 2026 (USD Billion)
  72. Asia-Pacific Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  73. Asia-Pacific Neurology Market, By Region, From 2021 to 2026 (USD Billion)
  74. Asia-Pacific Infectious diseases Market, By Region, From 2021 to 2026 (USD Billion)
  75. Asia-Pacific Diabetes Market, By Region, From 2021 to 2026 (USD Billion)
  76. Asia-Pacific Oncology Market, By Region, From 2021 to 2026 (USD Billion)
  77. Asia-Pacific Cardiovascular Market, By Region, From 2021 to 2026 (USD Billion)
  78. Asia-Pacific Other Therapeutic Areas Market, By Region, From 2021 to 2026 (USD Billion)
  79. China Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  80. China Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  81. India Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  82. India Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  83. Japan Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  84. Japan Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  85. South Korea Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  86. South Korea Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  87. Australia Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  88. Australia Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  89. Latin America Biopharmaceuticals Market, By Region, From 2021 to 2026 (USD Billion)
  90. Latin America Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  91. Latin America Monoclonal Antibodies (mAb) Market, By Region, From 2021 to 2026 (USD Billion)
  92. Latin America Erythropoietin Market, By Region, From 2021 to 2026 (USD Billion)
  93. Latin America Biotech Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  94. Latin America Recombinant Human (RH) Insulin Market, By Region, From 2021 to 2026 (USD Billion)
  95. Latin America Granulocyte colony-stimulating factor (G-CSF) Market, By Region, From 2021 to 2026 (USD Billion)
  96. Latin America Interferon Market, By Region, From 2021 to 2026 (USD Billion)
  97. Latin America Human growth hormones (HGH) Market, By Region, From 2021 to 2026 (USD Billion)
  98. Latin America Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  99. Latin America Neurology Market, By Region, From 2021 to 2026 (USD Billion)
  100. Latin America Infectious diseases Market, By Region, From 2021 to 2026 (USD Billion)
  101. Latin America Diabetes Market, By Region, From 2021 to 2026 (USD Billion)
  102. Latin America Oncology Market, By Region, From 2021 to 2026 (USD Billion)
  103. Latin America Cardiovascular Market, By Region, From 2021 to 2026 (USD Billion)
  104. Latin America Other Therapeutic Areas Market, By Region, From 2021 to 2026 (USD Billion)
  105. Brazil Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  106. Brazil Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  107. Argentina Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  108. Argentina Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  109. Mexico Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  110. Mexico Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  111. Middle East & Africa Biopharmaceuticals Market, By Region, From 2021 to 2026 (USD Billion)
  112. Middle East & Africa Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  113. Middle East & Africa Monoclonal Antibodies (mAb) Market, By Region, From 2021 to 2026 (USD Billion)
  114. Middle East & Africa Erythropoietin Market, By Region, From 2021 to 2026 (USD Billion)
  115. Middle East & Africa Biotech Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  116. Middle East & Africa Recombinant Human (RH) Insulin Market, By Region, From 2021 to 2026 (USD Billion)
  117. Middle East & Africa Granulocyte colony-stimulating factor (G-CSF) Market, By Region, From 2021 to 2026 (USD Billion)
  118. Middle East & Africa Interferon Market, By Region, From 2021 to 2026 (USD Billion)
  119. Middle East & Africa Human growth hormones (HGH) Market, By Region, From 2021 to 2026 (USD Billion)
  120. Middle East & Africa Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  121. Middle East & Africa Neurology Market, By Region, From 2021 to 2026 (USD Billion)
  122. Middle East & Africa Infectious diseases Market, By Region, From 2021 to 2026 (USD Billion)
  123. Middle East & Africa Diabetes Market, By Region, From 2021 to 2026 (USD Billion)
  124. Middle East & Africa Oncology Market, By Region, From 2021 to 2026 (USD Billion)
  125. Middle East & Africa Cardiovascular Market, By Region, From 2021 to 2026 (USD Billion)
  126. Middle East & Africa Other Therapeutic Areas Market, By Region, From 2021 to 2026 (USD Billion)
  127. Middle East Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  128. Middle East Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)
  129. Africa Biopharmaceuticals Market, By Product Type, From 2021 to 2026 (USD Billion)
  130. Africa Biopharmaceuticals Market, By Therapeutic Type, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample